tiprankstipranks
Amarin Leadership Changes Amidst VASCEPA Coverage Challenge
Company Announcements

Amarin Leadership Changes Amidst VASCEPA Coverage Challenge

Don't Miss our Black Friday Offers:

An announcement from Amarin (AMRN) is now available.

Patrick Holt has stepped down as President and CEO of Amarin Corporation plc, with Aaron Berg succeeding him in the role and joining the company’s board. Berg brings a wealth of experience from his previous leadership roles in the pharmaceutical industry, including a strong background in marketing and sales. Meanwhile, the company faces a challenge as a significant pharmacy benefit manager plans to remove VASCEPA from its Commercial national formularies, which currently accounts for about a quarter of the product’s U.S. prescription volume, although Medicare Part D coverage remains unaffected.

For detailed information about AMRN stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAmarin announces to present additional analysis from REDUCE-IT outcomes trial
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskAmarin Corporation: Q3 Highlights and Future Outlook
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App